Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Maternal serum analyte levels after first-trimester multifetal pregnancy reduction

Maternal serum analyte levels after first-trimester multifetal pregnancy reduction OBJECTIVE: Our purpose was to assess the effect of multifetal pregnancy reduction on maternal serum levels of analytes used for screening low-risk women for fetal chromosome abnormalities and neural tube defects. STUDY DESIGN: Peripheral blood samples were obtained between 15.0 and 20.9 weeks' gestation from 10 consecutive women who had undergone first-trimester multifetal pregnancy reduction. The samples were assayed for levels of α -fetoprotein, human chorionic gonadotropin, and unconjugated estriol. Analyte concentrations were interpreted within our maternal serum screening program. RESULTS: Levels of α -fetoprotein were significantly elevated in all samples. In each pregnancy levels of human chorionic gonadotropin and unconjugated estriol were consistent with the number of continuing gestations. CONCLUSIONS: First-trimester multifetal reduction does not alter second-trimester levels of human chorionic gonadotropin and unconjugated estriol. Further study is needed to determine whether these analytes could be used to screen pregnancies for fetal chromosome abnormalities after first-trimester multifetal reduction. (AM J OBSTET GYNECOL 1996;174:1072-4.) http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Obstetrics and Gynecology Wolters Kluwer Health

Maternal serum analyte levels after first-trimester multifetal pregnancy reduction

Download PDF
3 pages

Loading next page...
 
/lp/elsevier/maternal-serum-analyte-levels-after-first-trimester-multifetal-0IYJXd60GD

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 1996 Mosby, Inc.
ISSN
0002-9378
DOI
10.1016/S0002-9378(96)70353-8
Publisher site
See Article on Publisher Site

Abstract

OBJECTIVE: Our purpose was to assess the effect of multifetal pregnancy reduction on maternal serum levels of analytes used for screening low-risk women for fetal chromosome abnormalities and neural tube defects. STUDY DESIGN: Peripheral blood samples were obtained between 15.0 and 20.9 weeks' gestation from 10 consecutive women who had undergone first-trimester multifetal pregnancy reduction. The samples were assayed for levels of α -fetoprotein, human chorionic gonadotropin, and unconjugated estriol. Analyte concentrations were interpreted within our maternal serum screening program. RESULTS: Levels of α -fetoprotein were significantly elevated in all samples. In each pregnancy levels of human chorionic gonadotropin and unconjugated estriol were consistent with the number of continuing gestations. CONCLUSIONS: First-trimester multifetal reduction does not alter second-trimester levels of human chorionic gonadotropin and unconjugated estriol. Further study is needed to determine whether these analytes could be used to screen pregnancies for fetal chromosome abnormalities after first-trimester multifetal reduction. (AM J OBSTET GYNECOL 1996;174:1072-4.)

Journal

American Journal of Obstetrics and Gynecology – Wolters Kluwer Health

Published: Mar 1, 1996

References

  • Selective reduction of multifetal pregnancies
    Wapner, RJ; Davis, GH; Johnson, A
  • Embryo reduction in multifetal pregnancies using saline injection: comparison between the transvaginal and the transabdominal approach
    Yovel, I; Yaron, Y; Amit, A
  • First-trimester transabdominal multifetal pregnancy reduction: a report of two hundred completed cases
    Berkowitz, RL; Lynch, L; Lapinski, R; Bergh, P.
  • A report of 131 cases of multifetal pregnancy reduction
    Tabsh, KM.
  • Efficacy of transabdominal multifetal pregnancy reduction: collaborative experience among the world's largest centers
    Evans, MI; Dommergues, M; Wapner, RJ
  • Multifetal pregnancy reduction by transvaginal puncture: evaluation of the technique used in 134 cases
    Timor-Tritsch, IE; Peisner, DB; Monteagudo, A; Lerner, JP; Sharma, S.
  • Perinatal outcome after multifetal reduction to twins compared with nonreduced multiple gestations
    Melgar, CA; Rosenfeld, DL; Rawlinson, K; Greenberg, M.
  • Elevated maternal serum alpha-fetoprotein and amniotic fluid alpha-fetoprotein after multifetal pregnancy reduction
    Grau, P; Robinson, L; Tabsh, K; Crandall, BF.
  • Maternal serum α-fetoprotein and coagulation profiles after multifetal pregnancy reduction
    Lynch, L; Berkowitz, RL
  • Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG and unconjugated estriol: a prospective 2-year study
    Phillips, OP; Elias, S; Shulman, LP; Andersen, RN; Morgan, CD; Simpson, JL.
  • Maternal serum screening for fetal Down syndrome in the United States: a 1992 survey
    Palomaki, GE; Knight, GJ; McCarthy, J; Haddow, JE; Eckfeldt, JH.
  • Prospective intervention trial of a screening protocol to identify fetal trisomy 18 using maternal serum alpha-fetoprotein, unconjugated estriol and human chorionic gonadotropin
    Palomaki, GE; Knight, GJ; Haddow, JE; Canick, JA; Saller, DN; Panizza, DS.
  • American College of Obstetricians and Gynecologists Committee on Obstetric Practice. Down syndrome screening
  • Maternal plasma levels of human chorionic gonadotropin, oestradiol and progesterone in multifetal pregnancies before and after fetal reduction
    Johnson, MR; Abbas, A; Nicolaides, KH.
  • HCG, estriol and other maternal blood markers of fetal aneuploidy
    Cuckle, HS; Wald, NJ.